![]() |
||||||||
![]() |
||||
Read about the latest news from qd Solutions. qd Tips: Clinical Trials News: |
New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study- First Autologous Cellular Immunotherapy to Prolong Survival in Cancer - SEATTLE, July 28, 2010 /PRNewswire-FirstCall/ -- Dendreon Corporation announced today the publication of data from the pivotal Phase 3 IMPACT study in the , showing that... Posted on 29 July 2010 | 6:07 pm Study Analysis Identifies Potential Biomarkers of Velcade (Bortezomib) Activity in Patients with Relapsed Mantle Cell Lymphoma-- Data suggest possibility of more targeted approach to treatment with VELCADE-- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 29, 2010 - Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE... Posted on 29 July 2010 | 3:07 pm Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with SchizophreniaNEW YORK, July 29 /PRNewswire/ -- Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of... Posted on 29 July 2010 | 2:07 pm Generex Provides Positive Update on Generex Oral-lyn Pivotal Phase III TrialStudy has now achieved 75% of the required number of per-protocol completers WORCESTER, MA, July 28, 2010 (GlobeNewswire) – Generex Biotechnology Corporation (NasdaqCM:GNBT, www.generex.com), the leader in drug delivery for metabolic diseases... Posted on 29 July 2010 | 1:07 pm Chimerix CMX157 Shows Potential to Treat Multi-Drug Resistant HIV and Improve the Activity and Toxicity Profile of TenofovirRESEARCH TRIANGLE PARK, NC, July 28, 2010 – Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157... Posted on 29 July 2010 | 1:07 pm |
|